Drug General Information (ID: DDIFTM3KUB)
  Drug Name Iloprost Drug Info Salsalate Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antihypertensive Agents Antiinflammatory Agents
  Structure

 Mechanism of Iloprost-Salsalate Interaction (Severity Level: Moderate)
     Increased risk of bleeding Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Iloprost Salsalate
      Mechanism Risk of bleeding
Antiplatelet effects 
Risk of bleeding
Antiplatelet effects 
      Key Mechanism Factor 1
Factor Name Bleeding
Factor Description Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
      Mechanism Description
  • Increased risk of bleeding by the combination of Iloprost and Salsalate 

Recommended Action
      Management Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hemorrhagic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.

References
1 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
2 Product Information. Remodulin (treprostinil). United Therapeutics Corp, Silver Spring, MD.
3 Product Information. Ventavis (iloprost). Actelion Pharmaceuticals US Inc, South San Francisco, CA.